Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

external development spending decreased by $8.3 million for the same period.

General and administrative expenses were $3.0 million for the third quarter of 2009 and $3.5 million during the same period last year. For the nine months ended September 30, 2009, general and administrative expenses were $12.0 million, compared to $16.4 million for the same period in 2008. Personnel expenses decreased by $3.0 million in the first nine months of 2009 compared to the first nine months of 2008 primarily as a result of our restructuring program in the second quarter of 2009. Additionally, other non-personnel cost reductions have resulted in savings of approximately $1.2 million in the nine month period ending September 30, 2009 compared with the same period in the prior year.

The Company's balance sheet on September 30, 2009 reflected total assets of $75.9 million, including cash and investments of $63.7 million compared with balances at December 31, 2008 of $118.2 million and $101.5 million, respectively.

"We have made tremendous progress in our lead programs this past quarter," said Kevin C. Gorman, President and Chief Executive Officer. "After a very productive Type C meeting with the FDA, we rapidly launched our Daisy Petal study which is enrolling well. In addition, we've moved our VMAT-2 program into the clinic to determine if the ideal pharmacokinetic profile we have seen in animal models is achieved in humans."

Pipeline Highlights

Elagolix Update

The Company held a Type C meeting with the Food and Drug Administration (FDA) in August to discuss the non-menstrual pelvic pain scale proposed by the FDA and used in the Lilac Petal Study (0702). Based on this meeting, the Company modified the wording of the non-menstrual pain daily scale and launched a new clinical trial, the Daisy Petal Study (0901). This double-blind placebo-controlled clinical trial is designed to provide an a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... May 6 Vanda Pharmaceuticals Inc. (Nasdaq: ... Drug Administration (FDA) has granted marketing approval of Fanapt(TM) ... schizophrenia. The approval was supported by two placebo-controlled Phase ... control in patients with schizophrenia, as well as safety ...
... provide important insight for physicians in treating heart attack ... BSX ) today welcomed the publication of ... issue of the New England Journal of Medicine. ... Foundation with research grant support from Boston Scientific and ...
Cached Medicine Technology:FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 2FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 3FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 4FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 5FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 6FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 7Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... One of the most recent dietary trends ... diet. Originally meant for sufferers of gluten intolerance and celiac ... who are looking to get healthier by simply consuming foods ... kind of information erroneous, it also exposes those same consumers ... a drastic change in their food consumption habits. ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The new review ... program was created by Karen Brimeyer, who wanted to make ... , This guide is now easy to find in ... download. In this guide, the author of the new method ... , Daily Gossip writes in its review that the ...
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 Ms. Meriwether’s ... her. She certainly has an impressive resume to boost. ... Miss USA in 2012. However, she’s also a two ... Grad student. Nana trained for the 2008 Olympics and ... Miss USA website, “This six-foot beauty from Potomac, Maryland is ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... Ind., April 14 Conseco, Inc. (NYSE:,CNO) ... promoted to vice president,enterprise risk management, reporting ... actuary. Mr. Bischof is responsible for overseeing ... conjunction,with Conseco,s Enterprise Risk Management Committee., ...
... April 14 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), ... and audio web cast on Wednesday, April 30, 2008,at ... release of its,financial results for the first quarter ended ... 6:30 a.m. ET on Wednesday,April 30, 2008., To ...
... male hormone in the morning made more money , , MONDAY, ... finds that financial traders who wake up with high levels ... that day, probably because they feel more daring. , ... stress hormone cortisol tend to be more cautious. , "We ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... New York Times on skyrocketing biotech prices:, ... and will,spend $100 billion within a few years. ... because they don,t face generic competition once their,patents ...
... Cogdell Spencer,Inc. (NYSE: CSA ) announced today that ... on Monday, May 5, 2008. Cogdell Spencer,Inc. invites you ... May 6, 2008 at 10:00 a.m. (Eastern Time). The ... or (412) 858-4600,(international). In addition, the conference call can ...
... that hypertension should still be treated , , MONDAY, April ... are less likely to have headaches than those with ... one headache expert cautions that the new research does ... or stop taking their blood pressure medications. , The ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3
... The Professional Gold Package ... your laboratory. The package includes ... and automated system, starter package ... v-block adapter, specimen mounts 1/2" ...
... provides a versatile means of sectioning fresh ... The 1000 employs a vibrating blade principle ... The creation of artifacts, the alteration ... and other deleterious effects inherent in freezing ...
... The NEW Vibratome 3000 Plus Sectioning System ... or fixed, animal, or plant tissues. ... which allows sectioning without freezing or embedding. ... of morphology, the destruction of enzyme activities, ...
... 3000 Deluxe Sectioning System provides a versatile ... or plant tissues. The 3000 employs ... without freezing or embedding. The creation ... destruction of enzyme activities, and other deleterious ...
Medicine Products: